These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 39389599)

  • 21. Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma.
    Jamieson SM; Tsai P; Kondratyev MK; Budhani P; Liu A; Senzer NN; Chiorean EG; Jalal SI; Nemunaitis JJ; Kee D; Shome A; Wong WW; Li D; Poonawala-Lohani N; Kakadia PM; Knowlton NS; Lynch CR; Hong CR; Lee TW; Grénman RA; Caporiccio L; McKee TD; Zaidi M; Butt S; Macann AM; McIvor NP; Chaplin JM; Hicks KO; Bohlander SK; Wouters BG; Hart CP; Print CG; Wilson WR; Curran MA; Hunter FW
    JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)-a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma.
    Flach S; Howarth K; Hackinger S; Pipinikas C; Ellis P; McLay K; Marsico G; Forshew T; Walz C; Reichel CA; Gires O; Canis M; Baumeister P
    Br J Cancer; 2022 May; 126(8):1186-1195. PubMed ID: 35132238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma: A Nonrandomized Controlled Trial.
    Saba NF; Wong SJ; Nasti T; McCook-Veal AA; McDonald MW; Stokes WA; Anderson AM; Ekpenyong A; Rupji M; Abousaud M; Rudra S; Bates JE; Remick JS; Joshi NP; Woody NM; Awan M; Geiger JL; Shreenivas A; Samsa J; Ward MC; Schmitt NC; Patel MR; Higgins KA; Teng Y; Steuer CE; Shin DM; Liu Y; Ahmed R; Koyfman SA
    JAMA Oncol; 2024 Jul; 10(7):896-904. PubMed ID: 38780927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma circulating tumor DNA as a potential tool for disease monitoring in head and neck cancer.
    Egyud M; Sridhar P; Devaiah A; Yamada E; Saunders S; Ståhlberg A; Filges S; Krzyzanowski PM; Kalatskaya I; Jiao W; Stein LD; Jalisi S; Godfrey TE
    Head Neck; 2019 May; 41(5):1351-1358. PubMed ID: 30554450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment Strategy for Distant Synchronous Metastatic Head and Neck Squamous Cell Carcinoma.
    Tang E; Lahmi L; Meillan N; Pietta G; Albert S; Maingon P
    Curr Oncol Rep; 2019 Nov; 21(11):102. PubMed ID: 31728650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The potential of hydrogel-free tumoroids in head and neck squamous cell carcinoma.
    Wong M; Vasani S; Breik O; Zhang X; Kenny L; Punyadeera C
    Cancer Med; 2024 Aug; 13(16):e70129. PubMed ID: 39169896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ramucirumab in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma: a single-centre, phase 1/2 trial.
    Adkins D; Ley JC; Liu J; Oppelt P
    Lancet Oncol; 2024 Jul; 25(7):888-900. PubMed ID: 38851207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p-mTOR, p-ERK and PTEN Expression in Tumor Biopsies and Organoids as Predictive Biomarkers for Patients with HPV Negative Head and Neck Cancer.
    de Kort WWB; de Ruiter EJ; Haakma WE; Driehuis E; Devriese LA; van Es RJJ; Willems SM
    Head Neck Pathol; 2023 Sep; 17(3):697-707. PubMed ID: 37486536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics and Impact of HPV-Associated p16 Expression on Head and Neck Squamous Cell Carcinoma in Thai Patients.
    Jiarpinitnun C; Larbcharoensub N; Pattaranutaporn P; Chureemas T; Juengsamarn J; Trachu N; Lukerak S; Chansriwong P; Ngamphaiboon N
    Asian Pac J Cancer Prev; 2020 Jun; 21(6):1679-1687. PubMed ID: 32592364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
    Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dynamic profiling of immune microenvironment during anti-PD-1 immunotherapy for head and neck squamous cell carcinoma: the IPRICE study.
    Hélène C; Conrad O; Pflumio C; Borel C; Voegelin M; Bernard A; Schultz P; Onea MA; Jung A; Martin S; Burgy M
    BMC Cancer; 2023 Dec; 23(1):1209. PubMed ID: 38066522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient-derived three-dimensional culture techniques model tumor heterogeneity in head and neck cancer.
    Parikh AS; Yu VX; Flashner S; Okolo OB; Lu C; Henick BS; Momen-Heravi F; Puram SV; Teknos T; Pan Q; Nakagawa H
    Oral Oncol; 2023 Mar; 138():106330. PubMed ID: 36773387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
    Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL
    J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relevance of the time interval between surgery and adjuvant radio (chemo) therapy in HPV-negative and advanced head and neck carcinoma of unknown primary (CUP).
    Balk M; Rupp R; Mantsopoulos K; Allner M; Grundtner P; Mueller SK; Traxdorf M; Eckstein M; Speer S; Semrau S; Fietkau R; Iro H; Hecht M; Gostian AO
    BMC Cancer; 2021 Nov; 21(1):1236. PubMed ID: 34794411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynamics of cell-free tumour DNA correlate with treatment response of head and neck cancer patients receiving radiochemotherapy.
    Hilke FJ; Muyas F; Admard J; Kootz B; Nann D; Welz S; Rieß O; Zips D; Ossowski S; Schroeder C; Clasen K
    Radiother Oncol; 2020 Oct; 151():182-189. PubMed ID: 32687856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT study.
    Flanagan KC; Earls J; Hiken J; Wellinghoff RL; Ponder MM; McLeod HL; Westra WH; Vavinskaya V; Sutton L; Deichaite I; Macdonald OK; Welaya K; Wade J; Azzi G; Pippas AW; Slim J; Bank B; Sui X; Kossman SE; Shenkenberg TD; Alexander WL; Price KA; Ley J; Messina DN; Glasscock JI; Colevas AD; Cohen EEW; Adkins D; Duncavage EJ
    J Immunother Cancer; 2024 Nov; 12(11):. PubMed ID: 39489541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching 'liquid biopsy' and quantitative tumor modeling.
    Ng SP; Bahig H; Wang J; Cardenas CE; Lucci A; Hall CS; Meas S; Sarli VN; Yuan Y; Urbauer DL; Ding Y; Ikner S; Dinh V; Elgohari BA; Johnson JM; Skinner HD; Gunn GB; Garden AS; Phan J; Rosenthal DI; Morrison WH; Frank SJ; Hutcheson KA; Mohamed ASR; Lai SY; Ferrarotto R; MacManus MP; Fuller CD
    BMC Cancer; 2018 Sep; 18(1):903. PubMed ID: 30231854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiR-21 as prognostic biomarker in head and neck squamous cell carcinoma patients undergoing an organ preservation protocol.
    Arantes LM; Laus AC; Melendez ME; de Carvalho AC; Sorroche BP; De Marchi PR; Evangelista AF; Scapulatempo-Neto C; de Souza Viana L; Carvalho AL
    Oncotarget; 2017 Feb; 8(6):9911-9921. PubMed ID: 28039483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Post-treatment FDG PET-CT in head and neck carcinoma: comparative analysis of 4 qualitative interpretative criteria in a large patient cohort.
    Zhong J; Sundersingh M; Dyker K; Currie S; Vaidyanathan S; Prestwich R; Scarsbrook A
    Sci Rep; 2020 Mar; 10(1):4086. PubMed ID: 32139722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of immune response biomarkers (PD‑L1, p16, CD3+ and CD8+ TILs) in recurrent head and neck squamous cell carcinoma within previously irradiated areas.
    Pflumio C; Thomas J; Salleron J; Faivre JC; Borel C; Dolivet G; Sastre-Garau X; Geoffrois L
    Oncol Rep; 2021 Mar; 45(3):1273-1283. PubMed ID: 33432367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.